Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


22.08.2022

1 Am J Surg Pathol
1 Ann Oncol
1 Anticancer Drugs
1 BMC Cancer
1 Cancer Res
2 Clin Cancer Res
1 Gynecol Oncol
1 Int J Gynaecol Obstet
1 J Clin Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg Pathol

  1. MOMENI-BOROUJENI A, Song H, Irshaid L, Strickland S, et al
    Outcome-based Validation of Confluent/Expansile Versus Infiltrative Pattern Assessment and Growth-based Grading in Ovarian Mucinous Carcinoma.
    Am J Surg Pathol. 2022 Mar 2. pii: 00000478-990000000-00003.
    PubMed         Abstract available


    Ann Oncol

  2. KRISTELEIT RS, Moore K
    Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?
    Ann Oncol. 2022 Aug 11. pii: S0923-7534(22)03867.
    PubMed        


    Anticancer Drugs

  3. SUN D, Shang D, Miao P, Jiang Z, et al
    MiR-4284 inhibits sensitivity to paclitaxel in human ovarian carcinoma SKOV3ip1 and HeyA8 cells by targeting DMC1.
    Anticancer Drugs. 2022;33:701-709.
    PubMed         Abstract available


    BMC Cancer

  4. YIN J, Wen Y, Zeng J, Zhang Y, et al
    CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells.
    BMC Cancer. 2022;22:903.
    PubMed         Abstract available


    Cancer Res

  5. WANG Y, Xie H, Chang X, Hu W, et al
    Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer.
    Cancer Res. 2022 Aug 15. pii: 707741. doi: 10.1158/0008-5472.CAN-21-3819.
    PubMed         Abstract available


    Clin Cancer Res

  6. BANERJEE S, Michalarea V, Ang JE, Ingles Garces A, et al
    A phase I trial of CT900, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer.
    Clin Cancer Res. 2022 Aug 19. pii: 708154. doi: 10.1158/1078-0432.CCR-22-1268.
    PubMed         Abstract available

  7. HOLLIS RL, Meynert AM, Michie CO, Rye T, et al
    Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    Clin Cancer Res. 2022 Jun 13. pii: 704888. doi: 10.1158/1078-0432.CCR-22-0368.
    PubMed         Abstract available


    Gynecol Oncol

  8. THOMAS QD, Boussere A, Classe JM, Pomel C, et al
    Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
    PubMed         Abstract available


    Int J Gynaecol Obstet

  9. TRAVAGLINO A, Raffone A, Gencarelli A, Micheli M, et al
    Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
    Int J Gynaecol Obstet. 2021 Nov 27. doi: 10.1002/ijgo.14050.
    PubMed         Abstract available


    J Clin Oncol

  10. HAMPEL H, Yurgelun MB
    Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
    J Clin Oncol. 2022;40:2681-2692.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: